Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095184 Target Snapshot

Integrin alpha-4/beta-7 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
537Compounds
55Assays
0Approved Drugs
475.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Integrin alpha-4/beta-7 shows approved-linked disease relevance led by Crohn's disease. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P13612. Start with Crohn's disease, then reuse UniProt P13612 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Crohn's disease, then reuse UniProt P13612 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
Crohn's disease

Integrin alpha-4/beta-7 shows approved-linked disease relevance led by Crohn's disease. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with Crohn's disease because it currently carries approved-linked support. Linked drugs include ABRILUMAB, NATALIZUMAB, VEDOLIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Integrin alpha-4/beta-7 as ChEMBL target CHEMBL2095184, mapped to UniProt P13612. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Integrin alpha-4/beta-7
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095184
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P13612
Integrin alpha-4
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Integrin alpha-4/beta-7 is the right protein anchor across sources, using UniProt P13612 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Crohn's disease is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntegrin alpha-4/beta-7
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP13612
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntegrin alpha-4
UniProt AccessionP13612
Component TypeProtein
Sequence Length1032 aa

Integrin alpha-4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Integrin alpha-4/beta-7, mapped to UniProt P13612. ChEMBL maps the protein component as Integrin alpha-4. Sequence length is 1032 aa.

Mapped IDP13612
Review nameIntegrin alpha-4/beta-7
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Integrin alpha-4/beta-7 shows approved-linked disease relevance led by Crohn's disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Crohn's disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugABRILUMAB
Linked drugNATALIZUMAB
Linked drugVEDOLIZUMAB
Approved-linked Approved
multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugFIRATEGRAST
Linked drugNATALIZUMAB
Approved-linked Approved
relapsing-remitting multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugFIRATEGRAST
Linked drugNATALIZUMAB
Approved-linked Approved
ulcerative colitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugABRILUMAB
Linked drugVEDOLIZUMAB
Approved-linked Approved
inflammation
1 linked drug · 1 direct · 1 efficacy
Linked drugNATALIZUMAB
Late clinical Phase III
pouchitis
1 linked drug · 1 direct · 1 efficacy
Linked drugVEDOLIZUMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Crohn's disease because it currently carries approved-linked support. Linked drugs include ABRILUMAB, NATALIZUMAB, VEDOLIZUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCrohn's disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50473.0
KI1.0
EC501.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5877352 9.57 IC50 0.27 Preclinical
CHEMBL5946056 9.48 IC50 0.33 Preclinical
CHEMBL5904923 9.34 IC50 0.46 Preclinical
CHEMBL6035989 9.21 IC50 0.61 Preclinical
CHEMBL91485 9.12 IC50 0.75 Preclinical
CHEMBL5998447 9.05 IC50 0.89 Preclinical
CHEMBL5779177 9.01 IC50 0.98 Preclinical
CHEMBL5842689 8.91 IC50 1.23 Preclinical
CHEMBL4592659 8.85 EC50 1.4 Preclinical
CHEMBL6030719 8.81 IC50 1.53 Preclinical
Distribution

pChEMBL Value Distribution

25
5.0
34
5.5
59
6.0
73
6.5
93
7.0
76
7.5
33
8.0
25
8.5
7
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

55
Total Assays
432
Tested Compounds
2
Assay Types
Binding — 53 assays, 432 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 33 209 7.1
protein complex format 18 181 7.0
assay format 2 42 6.9
Functional — 2 assays, 16 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 16 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine